These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 28415689

  • 1. Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
    Krupka C, Lichtenegger FS, Köhnke T, Bögeholz J, Bücklein V, Roiss M, Altmann T, Do TU, Dusek R, Wilson K, Bisht A, Terrett J, Aud D, Pombo-Villar E, Rohlff C, Hiddemann W, Subklewe M.
    Oncotarget; 2017 May 30; 8(22):35707-35717. PubMed ID: 28415689
    [Abstract] [Full Text] [Related]

  • 2. CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia.
    Yakymiv Y, Augeri S, Fissolo G, Peola S, Bracci C, Binaschi M, Bellarosa D, Pellacani A, Ferrero E, Ortolan E, Funaro A.
    Cells; 2019 Dec 05; 8(12):. PubMed ID: 31817547
    [Abstract] [Full Text] [Related]

  • 3. CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1.
    Yakymiv Y, Augeri S, Bracci C, Marchisio S, Aydin S, D'Ardia S, Massaia M, Ferrero E, Ortolan E, Funaro A.
    Sci Rep; 2021 Oct 27; 11(1):21230. PubMed ID: 34707185
    [Abstract] [Full Text] [Related]

  • 4. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
    Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S.
    Cytotherapy; 2020 Jul 27; 22(7):369-376. PubMed ID: 32303428
    [Abstract] [Full Text] [Related]

  • 5. CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice.
    Williams BA, Wang XH, Leyton JV, Maghera S, Deif B, Reilly RM, Minden MD, Keating A.
    Haematologica; 2018 Oct 27; 103(10):1720-1729. PubMed ID: 29976748
    [Abstract] [Full Text] [Related]

  • 6. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Hutmacher C, Volta L, Rinaldi F, Murer P, Myburgh R, Manz MG, Neri D.
    Leuk Res; 2019 Sep 27; 84():106178. PubMed ID: 31326578
    [Abstract] [Full Text] [Related]

  • 7. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL, Amberger DC, Doraneh-Gard F, Sutanto W, Guenther T, Schmohl J, Schuster F, Salih H, Babor F, Borkhardt A, Schmetzer H.
    J Immunother; 2017 Sep 27; 40(6):224-248. PubMed ID: 28557814
    [Abstract] [Full Text] [Related]

  • 8. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
    Koerner SP, André MC, Leibold JS, Kousis PC, Kübler A, Pal M, Haen SP, Bühring HJ, Grosse-Hovest L, Jung G, Salih HR.
    Leukemia; 2017 Feb 27; 31(2):459-469. PubMed ID: 27435001
    [Abstract] [Full Text] [Related]

  • 9. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
    Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, Mo X, Groh V, Whitman SP, Konopitzky R, Kössl C, Bucci D, Lucas DM, Yu J, Caligiuri MA, Blum W, Adam PJ, Borges E, Rueter B, Heider KH, Marcucci G, Muthusamy N.
    Blood; 2016 Jun 09; 127(23):2879-89. PubMed ID: 27013443
    [Abstract] [Full Text] [Related]

  • 10. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
    Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, Högberg C, Rissler M, Wunderlich M, Juliusson G, Richter J, Sjöström K, Bhatia R, Mulloy JC, Järås M, Fioretos T.
    Proc Natl Acad Sci U S A; 2015 Aug 25; 112(34):10786-91. PubMed ID: 26261316
    [Abstract] [Full Text] [Related]

  • 11. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
    Habibi-Anbouhi M, Kafi Z, Ghazizadeh L, Kharazi S, Behdani M, Faraji F, Shokrgozar MA.
    Iran J Allergy Asthma Immunol; 2019 Oct 30; 18(6):679-687. PubMed ID: 32245312
    [Abstract] [Full Text] [Related]

  • 12. The Monoclonal Anti-CD157 Antibody Clone SY11B5, Used for High Sensitivity Detection of PNH Clones on WBCs, Fails to Detect a Common Polymorphic Variant Encoded by BST-1.
    Blaha J, Schwarz K, Fischer C, Schauwecker P, Höchsmann B, Schrezenmeier H, Anliker M.
    Cytometry B Clin Cytom; 2018 Jul 30; 94(4):652-659. PubMed ID: 29360268
    [Abstract] [Full Text] [Related]

  • 13. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
    Martner A, Rydström A, Riise RE, Aurelius J, Brune M, Foà R, Hellstrand K, Thorén FB.
    Oncotarget; 2015 Dec 15; 6(40):42569-74. PubMed ID: 26544512
    [Abstract] [Full Text] [Related]

  • 14. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
    Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ, Thomas D, Fabri L, Vairo G, Lock RB, Lopez AF, Nash AD.
    Leukemia; 2014 Nov 15; 28(11):2213-21. PubMed ID: 24705479
    [Abstract] [Full Text] [Related]

  • 15. An immunohistochemical, enzymatic, and behavioral study of CD157/BST-1 as a neuroregulator.
    Higashida H, Liang M, Yoshihara T, Akther S, Fakhrul A, Stanislav C, Nam TS, Kim UH, Kasai S, Nishimura T, Al Mahmuda N, Yokoyama S, Ishihara K, Gerasimenko M, Salmina A, Zhong J, Tsuji T, Tsuji C, Lopatina O.
    BMC Neurosci; 2017 Mar 24; 18(1):35. PubMed ID: 28340569
    [Abstract] [Full Text] [Related]

  • 16. CD157: From immunoregulatory protein to potential therapeutic target.
    Ortolan E, Augeri S, Fissolo G, Musso I, Funaro A.
    Immunol Lett; 2019 Jan 24; 205():59-64. PubMed ID: 29936181
    [Abstract] [Full Text] [Related]

  • 17. The CD157-integrin partnership controls transendothelial migration and adhesion of human monocytes.
    Lo Buono N, Parrotta R, Morone S, Bovino P, Nacci G, Ortolan E, Horenstein AL, Inzhutova A, Ferrero E, Funaro A.
    J Biol Chem; 2011 May 27; 286(21):18681-91. PubMed ID: 21478153
    [Abstract] [Full Text] [Related]

  • 18. ADP ribosyl-cyclases (CD38/CD157), social skills and friendship.
    Chong A, Malavasi F, Israel S, Khor CC, Yap VB, Monakhov M, Chew SH, Lai PS, Ebstein RP.
    Psychoneuroendocrinology; 2017 Apr 27; 78():185-192. PubMed ID: 28212520
    [Abstract] [Full Text] [Related]

  • 19. Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.
    Stefańczyk SA, Hagelstein I, Lutz MS, Müller S, Holzmayer SJ, Jarjour G, Zekri L, Heitmann JS, Salih HR, Märklin M.
    Blood Cancer J; 2024 Apr 18; 14(1):67. PubMed ID: 38637557
    [Abstract] [Full Text] [Related]

  • 20. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.
    Schmiedel BJ, Nuebling T, Steinbacher J, Malinovska A, Wende CM, Azuma M, Schneider P, Grosse-Hovest L, Salih HR.
    J Immunol; 2013 Jan 15; 190(2):821-31. PubMed ID: 23241893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.